Curaleaf Holdings Inc banner
C

Curaleaf Holdings Inc
OTC:CURLF

Watchlist Manager
Curaleaf Holdings Inc
OTC:CURLF
Watchlist
Price: 2.28 USD -3.8% Market Closed
Market Cap: $1.7B

Relative Value

There is not enough data to reliably calculate the relative value of CURLF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CURLF Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

CURLF Competitors Multiples
Curaleaf Holdings Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Curaleaf Holdings Inc
OTC:CURLF
4.8B USD 1.5 -6 22.1 349.8
US
Eli Lilly and Co
NYSE:LLY
993.5B USD 15.2 48.1 32.4 34.5
US
Johnson & Johnson
NYSE:JNJ
590.8B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
292.8B CHF 4.8 31.3 13.2 15.4
UK
AstraZeneca PLC
LSE:AZN
237.2B GBP 5.5 31.7 17.5 24.6
CH
Novartis AG
SIX:NOVN
244.9B CHF 5.6 22.6 13.9 17.9
US
Merck & Co Inc
NYSE:MRK
307.1B USD 4.7 16.8 10.5 12.3
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 3.7 11.3 8.3 9.8
US
Pfizer Inc
NYSE:PFE
153.9B USD 2.5 19.8 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
123.1B USD 2.6 17.5 7.3 9
P/E Multiple
Earnings Growth PEG
CA
C
Curaleaf Holdings Inc
OTC:CURLF
Average P/E: 24.6
Negative Multiple: -6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.3
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.7
26%
1.2
CH
Novartis AG
SIX:NOVN
22.6
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.8
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
7%
1.6
US
Pfizer Inc
NYSE:PFE
19.8
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
C
Curaleaf Holdings Inc
OTC:CURLF
Average EV/EBITDA: 43.7
22.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.4
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.5
11%
1.6
CH
Novartis AG
SIX:NOVN
13.9
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.5
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.3
7%
1.2
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-12%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
C
Curaleaf Holdings Inc
OTC:CURLF
Average EV/EBIT: 121.6
349.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.5
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.4
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
24.6
24%
1
CH
Novartis AG
SIX:NOVN
17.9
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
8%
1.2
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-6%
N/A